The Thailand--Myanmar border is endemic for malaria with high-grade antimalarial drug resistance \[[@CIW388C1], [@CIW388C2]\]. After the failures of chloroquine and sulfadoxine-pyrimethamine, mefloquine was introduced as the treatment of uncomplicated *Plasmodium falciparum* malaria in 1985. However, resistance developed rapidly \[[@CIW388C2], [@CIW388C3]\], mediated by amplification of the multidrug-resistance gene 1 (*Pfmdr1*) \[[@CIW388C4]\]. In 1992 the cure rate of high-dose mefloquine monotherapy had fallen to 50% \[[@CIW388C5]\]. The first artemisinin-based combination treatment (ACT), mefloquine plus artesunate (MAS3), was deployed in 1994 in camps for displaced people \[[@CIW388C2]\]. The new treatment was highly efficacious and accompanied by a large and sustained reduction in *P. falciparum* incidence \[[@CIW388C6], [@CIW388C7]\] despite continued presence of effective malaria vectors. A similar impact was documented in the population of migrant workers living along the border \[[@CIW388C8]\]. The diminishing proportion of infections carrying multiple parasite clones also suggested reduced transmission \[[@CIW388C9]\].

Resistance to artemisinin derivatives, characterized by delayed parasite clearance in artesunate-treated patients, was first recognized in western Cambodia in 2007 \[[@CIW388C10], [@CIW388C11]\] and later on the Thailand--Myanmar border where it was found to be heritable \[[@CIW388C12]\] and associated with a selective sweep on chromosome 13 of the *P. falciparum* genome \[[@CIW388C13]\] due to mutations in the propeller region of the Kelch gene (*K13*) \[[@CIW388C14], [@CIW388C15]\]. However, the link between *K13* polymorphism and treatment failure was not clearly established, and some authors have contested whether use of the term "artemisinin resistance" is justified \[[@CIW388C16]--[@CIW388C18]\]. This uncertainty may have contributed to the failure to contain artemisinin resistance in the greater Mekong area.

Two recent studies have provided some evidence that *K13* mutations are involved in combination with other mutations in the declining efficacy of 3-day dihydroartemisinin (DHA)--piperaquine in Cambodia \[[@CIW388C19]\]. An observational cohort study reported that treatment failure rates were higher in patients infected with parasites carrying the *K13* C580Y mutation compared with the R539T mutation, but there were only 4 wild-type infections in that study. Two additional mutations (MAL13:1718319 and MAL10:688956), associated with parasite clearance rate in a genome wide association (GWAS) study \[[@CIW388C20]\], were in strong linkage disequilibrium with C580Y. The authors concluded that this triple mutant genotype might have contributed to the failures observed. A second study of 241 patients showed falciparum malaria recrudescence was associated with increased piperaquine in vitro 50% inhibitory concentrations and the presence of *K13* mutations at 3 Cambodian sites \[[@CIW388C21]\] where isolates with multiple copies of *Pfmdr1* are rare \[[@CIW388C21]\].

In contrast to Cambodia, *P. falciparum* malaria parasites along the Thailand--Myanmar border frequently have multiple copies of *Pfmdr1* \[[@CIW388C4], [@CIW388C22]\]. The MAS3 combination has been deployed successfully as a first-line regimen for more than 15 years, but failure rates in recent years have risen. To determine the factors contributing to declining ACT efficacy, we studied 1005 falciparum malaria patients treated with MAS3 between 2003 and 2013.

METHODS {#s2}
=======

Patient Recruitment {#s2a}
-------------------

The study was designed for the longitudinal monitoring of MAS3 efficacy in prospectively enrolled patients presenting to the clinics of the Shoklo Malaria Research Unit \[[@CIW388C23]\] with uncomplicated *P. falciparum* malaria, excluding pregnant women, patients with severe malaria \[[@CIW388C24]\] or \>4% infected red blood cells, and those who had been treated with mefloquine in the previous 60 days. All patient treatments were supervised. Oral artesunate (Guilin Pharmaceutical Co., People\'s Republic of China), was given at a dose of 4 mg/kg/day for 3 days. Mefloquine (Roche, Switzerland, or CIPLA, India) was given either as split doses of 15 mg/kg and 10 mg/kg or 8 mg/kg once a day for 3 days \[[@CIW388C25]\]. On the first treatment day (day 0) a full clinical examination was performed; parasitemia and hematocrit were measured from capillary blood. Blood smears were microscopically examined daily until negative. Patients were seen weekly for 6 weeks. At each visit symptoms were recorded and a capillary blood sample was obtained for malaria smear and hematocrit. Dried blood spots for parasite genotyping were collected on grade 3 MM Whatman paper (Whatman, United Kingdom) at the first visit and in case of recurrence. Recurrence was defined by the occurrence of parasitemia during follow-up due either to a recrudescence or a reinfection. In 2013 single-dose primaquine as a gametocytocide (0.25 mg/kg) was added routinely on the first day of treatment.

Parasite Genotyping {#s2b}
-------------------

Parasite DNA was extracted and genotyped at 3 polymorphic loci (MSP1, MSP2, and GLURP) to distinguish recrudescence from reinfection \[[@CIW388C26]\]. We determined *Pfmdr1* copy number using quantitative polymerase chain reaction (PCR) and *K13* polymorphisms by direct sequencing of PCR products (see [Supplementary Methods](http://cid.oxfordjournals.org/lookup/suppl/doi:10.1093/cid/ciw388/-/DC1)). *Pfmdr1* and *K13* sequencing were done retrospectively after patient recruitment was completed.

Statistical Analyses {#s2c}
--------------------

Data were analyzed using Stata 14 (StataCorp, College Station, Texas). Normally distributed data were compared using Student *t* test and nonnormally distributed data were compared using the Mann--Whitney rank sum test. Categorical variables were assessed using χ^2^ tests. Analysis of variance was used to compare 3 or more groups. We used logistic regression to examine the association between each potential risk factor and used outcome and multiple logistic regression to analyze resulting risk factors. Survival time data were assessed using Cox regression. The population attributable fraction (PAF) for falciparum malaria recrudescence was calculated for *K13* mutations and *Pfmdr1* amplification individually and then for the marker combination using the formula 1--(1--PAF*~K13~*) × (1--PAF*~Pfmdr1~*). We censored patients with indeterminate genotypes, new infections with *P. falciparum*, or those lost to follow-up.

Ethical Approval {#s2d}
----------------

The Oxford Tropical Research Ethics Committee (OXTREC 562-15) and the faculty of Tropical Medicine, Mahidol University (MUTM 2015-019-01) gave ethical approval for the study.

RESULTS {#s3}
=======

Patients {#s3a}
--------

Between January 2003 and December 2013, 1022 patients were recruited, and 1005 remained in the study (Figure [1](#CIW388F1){ref-type="fig"}). Overall, 290 (28.8%) patients did not complete the full 42 days but were included in survival analyses. There were significant changes in gender ratio, age, duration of symptoms, and admission temperatures over the recruitment period, with an increasing proportion of older febrile male patients over time ([Supplementary Table 1](http://cid.oxfordjournals.org/lookup/suppl/doi:10.1093/cid/ciw388/-/DC1)). The proportion of patients with fever at admission (tympanic temperature ≥37.5°C) rose significantly from 26.2% in 2003 to 65.4% in 2013 (*P* = .005). There was also an increase in the median duration of symptoms before presentation from 2 days in 2003 to 3 days in 2013 (*P* = .04). Figure 1.Patient flow diagram after 3-day treatment with mefloquine plus artesunate.

Clinical Responses {#s3b}
------------------

MAS3 was well tolerated and cleared the clinical symptoms rapidly. By 24 hours 84.3% (95% confidence interval \[CI\], 81.6, 86.7) and by 72 hours 98.0% (95% CI, 95.2, 99.1) of patients were afebrile. There was no change in fever clearance times over the study period. The mean fractional reduction in hematocrit from baseline to day 7 did not differ significantly by year (test for trend *P* = .08). Risk factors associated with anemia (hematocrit \<30%) on admission were pretreatment gametocytemia (adjusted odds ratio \[aOR\], 9.43; 95% CI, 5.45, 16.34; *P* \< .0001), age \<13 years (aOR 3.77; 95% CI, 2.17, 6.56; *P* \< .0001), and female gender (aOR 2.18; 95% CI, 1.28, 3.72; *P* = .004). No patient in the cohort developed severe malaria, and there were no deaths.

*K13* Sequencing {#s3c}
----------------

*K13* sequences from 699 (68.5%) admission parasite isolates and 112 (59.9%) recurrent isolates were analyzed ([Supplementary Table 2](http://cid.oxfordjournals.org/lookup/suppl/doi:10.1093/cid/ciw388/-/DC1)). In the admission infections, 24 different nonsynonymous polymorphisms were detected, including 20 in the propeller region (Figure [2](#CIW388F2){ref-type="fig"} and [Supplementary Table 3](http://cid.oxfordjournals.org/lookup/suppl/doi:10.1093/cid/ciw388/-/DC1)). No sample had more than 1 mutation. The most frequent mutations were C580Y (10.4%) and E252Q (8.3%). The proportion of infections caused by isolates with any *K13* polymorphism increased from 6.7% (1/15; 95% CI, .2, 31.9) in 2003 to 83.9% (52/62; 95% CI, 72.3, 92.0) in 2013 (*P* \< .001; Figure [3](#CIW388F3){ref-type="fig"}). During the period 2005--2009, the E252Q mutation was most common, but from 2010 the *K13* propeller mutations (notably C580Y) predominated (Figure [2](#CIW388F2){ref-type="fig"}*A* and 2*B*). More recurrent isolates had *K13* mutations (81/112 \[72.3%\]) compared with admission isolates (314/699 \[44.9%\]; *P* \< .0001). In the recurrent isolates, more recrudescent isolates also had *K13* mutant alleles compared with reinfections (65/76 \[85.5%\] vs 12/24 \[50%\]; *P* \< .001). Figure 2.*A*, Primary amino acid positions and frequencies of *K13* mutations. (*B*) Annual proportions of *K13* propeller mutations (summed) and 4 individual genotypes (for which n \> 25). Figure 3.Annual proportions of day 42 polymerase chain reaction (PCR)--adjusted cure rates, summed *K13* mutations, and amplified *Pfmdr1*. Abbreviations: ACT, artemisinin-based combination treatment; SNP, single-nucleotide polymorphism; WHO, World Health Organization.

*Pfmdr1* Copy Number {#s3d}
--------------------

*Pfmdr1* copy numbers were measured in 726 (71.4%) admission isolates and 65 (34.8%) recurrent isolates ([Supplementary Table 2](http://cid.oxfordjournals.org/lookup/suppl/doi:10.1093/cid/ciw388/-/DC1)). The proportion of infections caused by parasites with multiple (\>1) *Pfmdr1* copies on admission doubled from 32.4% (95% CI, 17.4, 50.5) in 2003 to 64.7% (95% CI, 46.5, 80.3) in 2013 (*P* = .031; Figure [3](#CIW388F3){ref-type="fig"}). There was no significant difference in the distribution of *Pfmdr1* copy number with gender or age. Significantly more recurrent isolates had multiple copies of *Pfmdr1* 53/65 (81.5%) compared with admission isolates 377/726 (51.9%; *P* \< .001). Among these recurrent isolates, more recrudescent isolates also had multiple copies of *Pfmdr1* compared with reinfections (38/42 \[90.5%\] vs 8/13 \[61.5%\]; *P* = .002).

Our study did not characterize the single nucleotide polymorphisms of the *Pfmdr1* gene because these relevant single-nucleotide polymorphisms (SNPs) are rare in Thailand \[[@CIW388C27]\] and mefloquine resistance is driven by copy number changes on a *Pfmdr1* wild-type background \[[@CIW388C4], [@CIW388C28]--[@CIW388C30]\]. Isolates carrying wild-type *K13* were associated with single-copy *Pfmdr1*, while *K13* mutations were associated with amplified *Pfmdr1* (Fisher exact test, *P* \< .001) ([Supplementary Figure 1](http://cid.oxfordjournals.org/lookup/suppl/doi:10.1093/cid/ciw388/-/DC1)).

The success rate for genotyping of *K13* and *Pfmdr1* was lower in recurrent infections because of significantly lower parasitemia (*P* = .0004) and thus much lower parasite DNA concentrations.

Parasite Clearance {#s3e}
------------------

Clearance data were available for 957 patients (95.2%). There was a significant increase in the proportion of patients who were parasitemic at day 3 (*P* \< .001, test for trend; Table [1](#CIW388TB1){ref-type="table"}). Multivariate analysis showed that mutation in the *K13* gene was the strongest risk factor for day 3 positivity, with later year of treatment, higher parasitemia, higher hematocrit, and fever on admission (but not *Pfmdr1* amplification) as independent risk factors (Table [2](#CIW388TB2){ref-type="table"}). *K13* propeller mutations were stronger predictors of day 3 positivity, and the 3 most common propeller mutations (C580Y, N458Y, and R561H) were each significantly associated with day 3 positivity (Table [2](#CIW388TB2){ref-type="table"}). Table 1.Parasitological Responses to Mefloquine--Artesunate by YearYears20032004200520062007200820092010201120122013Completed treatment (n)42143694949164112845316476Proportion of day 3 blood slide positive (%)^a^2/42 (4.8)2/137 (1.5)4/68 (5.9)2/48 (4.2)0/47 (0)9/154 (5.8)20/105 (19.0)13/74 (17.6)10/49 (20.4)54/157 (34.4)29/76 (38.2)Proportion of day 4 blood slide positive (%)^a^0/42 (0)0/137 (0)0/68 (0)0/48 (0)0/47 (0)3/151 (2.0)4/104 (3.8)1/72 (1.4)3/48 (6.3)14/153 (9.2)6/74 (8.1)Unadjusted cure rate % (95% CI)10073.2 (62.4,81.3)81.1 (65.4,90.2)86.9 (67.6,95.1)91.0 (74.6,97.0)91.6 (84.6,95.5)79.3 (67.0,87.5)84.4 (72.7,91.3)43.6 (23.9,61.9)67.6 (59.3,74.6)61.4 (47.0,73.0)Polymerase chain reaction--adjusted cure rates (95% CI)10089.8 (82.3,94.2)89.5 (74.9,95.8)94.2 (78.8,98.5)94.1 (78.5,98.5)94.6 (89.0,97.4)89.3 (79.5,94.5)84.4 (72.7,91.3)50.9 (32.9,66.4)70.3 (62.0,77.0)81.1 (68.4,89.1)Days to recrudescence Median (range)...21 (15,24)24 (14,49)22 (22)31 (28,34)22 (19,26)24 (14,37)24.5 (17,38)21 (14,41)21 (7,36)21 (21,35)Days to reinfection Median (range)...37 (13,49)40 (28,49)42 (21,49)41 (35,47)37 (32,42)36.5 (22,49)...45.5 (44,49)30 (25,32)21 (14,42)[^1][^2] Table 2.Predictors for Persistent Day 3 Asexual Parasitemia Following Mefloquine--Artesunate TreatmentRisk FactorAdjusted Odds Ratio95% Confidence Interval*P* ValueHematocrit on admission1.041.00, 1.09.04Year of recruitment1.141.02, 1.27.02Log parasitemia on admission1.421.20, 1.68\<.001Fever (threshold of 37.5°C on admission)2.501.50, 4.18\<.001Any *K13* mutant6.593.53, 12.30\<.001Subsets of *K13* mutants^a^ Any *K13* propeller mutant9.604.86, 18.95\<.001 Isolates with E252Q2.25.91, 5.58.08 Isolates with C580Y7.613.42, 16.95\<.001 Isolates with N458Y8.753.10, 24.75\<.001 Isolates with R561H14.985.35, 41.92\<.001[^3][^4]

Cure Rates {#s3f}
----------

Of the 186 patients with recurrent *P. falciparum* infections, there were 117 (62.9%) recrudescences and 53 (28.5%) reinfections, with 2 indeterminate results, 1 amplification failure, and 13 missing samples. PCR-adjusted parasitological efficacy at day 42 remained above or close to 90% from 2003 to 2009 but declined sharply thereafter (test for trend, *P* \< .001; Table [1](#CIW388TB1){ref-type="table"}, Figure [3](#CIW388F3){ref-type="fig"}). There was a similar trend for recurrence (PCR unadjusted) rate. The lowest cure rates were recorded in 2011 when PCR-adjusted and unadjusted cure rates fell to 43.6% and 50.9%, respectively.

Predictors for Recrudescence {#s3g}
----------------------------

In a Cox regression model, increased *Pfmdr1* copy number and *K13* mutation were significant independent predictors of falciparum malaria recrudescence (with a multiplicative effect when in combination) along with year of recruitment and age (Table [3](#CIW388TB3){ref-type="table"}). The risk of recrudescence was even higher for *K13* propeller mutations as a group and for the 3 most common individual propeller mutations (C580Y, N458Y, and R561H; Table [3](#CIW388TB3){ref-type="table"}). Table 3.Predictors for *Plasmodium falciparum* Recrudescence by Day 42 Following Mefloquine--ArtesunateRisk FactorAdjusted Hazard Ratio95% Confidence Interval*P* ValueAge0.97.95, .99.003Year of recruitment1.201.10, 1.44.001Multiple *Pfmdr1* copy number (\>1)2.681.52, 4.75.001Any *K13* mutant3.841.77, 8.36.001Subsets of *K13* mutants^a^ Any *K13* propeller mutant4.762.11, 10.75\<.001 *K13* E252Q2.831.03, 7.75.04 *K13* C580Y5.042.00, 12.75.001 *K13* R561H5.882.24, 15.40\<.001 *K13* N458Y7.202.56, 20.24\<.001Compound genotypes^b^ Multiple *Pfmdr1* + wild type *K13*3.27.84, 12.65.09 Single *Pfmdr1* + *K13* propeller mutant5.731.54, 21.26.009 Multiple *Pfmdr1* + *K13* propeller mutant14.053.99, 49.48\<.001[^5][^6][^7]

Cure rates were highest for infections with isolates with single-copy *Pfmdr1* gene and wild-type *K13* (97.8%) and lowest in patients with multiple copies of *Pfmdr1* and any *K13* propeller SNP (57.8%; Table [4](#CIW388TB4){ref-type="table"}, Figures [4](#CIW388F4){ref-type="fig"} and [Supplementary Figure 2](http://cid.oxfordjournals.org/lookup/suppl/doi:10.1093/cid/ciw388/-/DC1)). Cure rates declined markedly in recent years as the prevalence of *K13* mutations rose ([Supplementary Figure 2](http://cid.oxfordjournals.org/lookup/suppl/doi:10.1093/cid/ciw388/-/DC1)). Table 4.Day 42 Polymerase Chain Reaction--Adjusted Adequate Clinical and Parasitological Response Rates Determined by Survival Analysis for 4 Compound GenotypesGenotypeCure Rate95% Confidence IntervalSingle *Pfmdr1* + wild-type *K13*97.8(93.3, 99.3)Multiple *Pfmdr1* + wild-type *K13*93.1(86.0, 96.7)Single *Pfmdr1* + *K13* propeller mutant78.5(65.6, 87.0)Multiple *Pfmdr1* + *K13* propeller mutant57.8(45.4, 68.3) Figure 4.Kaplan--Meier curves showing cumulative proportions of patients free from recrudescence stratified by presence of *Pfmdr1* copy number and *K13* genotype. The numbers in parentheses are the recrudescences during the indicated time. *K13* Prop refers to samples with mutation in the *K13* propeller.

The PAFs (equivalent to the percentage reduction in recrudescent infections that would occur if these mutations were not present) for *K13* and *Pfmdr1* amplification were 69.0 and 41.9%, respectively. The PAF for the 2 factors in combination was 82%. Hence these 2 factors alone explain almost entirely the increased ACT treatment failure rate observed in this population.

Pre- and Post-treatment Gametocytemia {#s3h}
-------------------------------------

The proportions of patients presenting with pre-treatment gametocytes or with post-treatment gametocytemia and the associated risk factors are shown in the [Supplementary Materials](http://cid.oxfordjournals.org/lookup/suppl/doi:10.1093/cid/ciw388/-/DC1) ([Supplementary Tables 1, 1.1 and 1.2](http://cid.oxfordjournals.org/lookup/suppl/doi:10.1093/cid/ciw388/-/DC1)). There was no association between the presence of *K13* propeller mutations (aOR 1.02; 95% CI, .47, 2.19) or multiple copies of *Pfmdr1* (aOR 1.28; 95% CI, .75, 2.17) and gametocytemia, either at admission or during follow-up.

DISCUSSION {#s4}
==========

MAS3 for the treatment of uncomplicated *P. falciparum* malaria has had a remarkable therapeutic longevity and a dramatic impact on morbidity and mortality on the Thailand--Myanmar border. When artesunate was introduced in 1991, mefloquine was a failing drug, the incidence of falciparum malaria was rising, and most parasite isolates had multiple copies of *Pfmdr1* associated with mefloquine resistance \[[@CIW388C4]\]. After deployment of this ACT in 1994, mefloquine recovered its efficacy, and less fit isolates with multiple *Pfmdr1* copies were replaced by single copy--containing isolates \[[@CIW388C31]\]. High cure rates were then sustained for more than a decade \[[@CIW388C22], [@CIW388C32]\]. In 2006, 53% of patients presenting with uncomplicated falciparum malaria had infections with multiple copies of *Pfmdr1* \[[@CIW388C22]\]. The rise in prevalence of *P. falciparum* parasites with *K13* propeller mutations was the definitive event that led to the demise of MAS3. The temporal sequence of *K13* selection is informative. The E252Q mutation (which is located on the stem region of the *K13* gene; Figure [2](#CIW388F2){ref-type="fig"}*A*), associated with moderate slowing of parasite clearance \[[@CIW388C15]\], predominated before 2010. Then parasites with the E252Q mutation were progressively overtaken by parasites with *K13* propeller mutations, conferring greater reductions in parasite clearance rates. The main propeller mutation was C580Y, a polymorphism common in Cambodia \[[@CIW388C14], [@CIW388C15]\]. The E252Q mutation was associated with a moderate increase in risk of treatment failure, suggesting that the selective advantage of the *K13* mutation is proportional to the degree of parasite clearance prolongation. It is possible that genetic changes outside the *K13* locus have contributed to the emergence of artemisinin resistance and the selection of *K13* mutations \[[@CIW388C20]\]. It remains to be seen whether parasite genotypes with even slower clearance will become established while ACTs remain the mainstay of antimalarial treatment.

The large body of data presented here strongly support the hypothesis that there is a substantial impact of *K13* mutations on treatment failure. *K13* mutations in admission samples are associated with a failure rate of 21.5%. In combination with multiple copies of *Pfmdr1*, this rises to 42.2%. The sharp decline in MAS3 cure rates temporally corresponds with the emergence of *K13* propeller mutant isolates on a long-standing genetic background of *Pfmdr1* amplification. The proportion of treatment failures that can be attributed to *K13* mutations and multiple copies of *Pfmdr1* (ie, PAF) is 82%. Hence, these 2 factors alone explain the majority of increase in treatment failure observed. Other parasite genetic factors that our study was not designed to detect or changes in the demographics of the patient population may have contributed to the 18% of unexplained variation in treatment failure.

We highlight 3 additional features of particular interest. First, *K13* mutations and *Pfmdr1* amplification have a multiplicative (rather than an additive) effect on risk of treatment failure. Synergy between these 2 resistance determinants may help to explain why failure rate declined precipitously in 2009---parasites carrying both markers only became common as *K13* mutations rose in frequency. Second, in contrast to the 2 Cambodian studies, we observed multiple *K13* mutations in this study. These data demonstrate significant heterogeneity in the impact of different *K13* mutations on treatment failure. A mutation outside the *K13* propeller (E252Q) increased treatment failure relative to wild-type parasites, but the 3 common propeller mutations had a much greater effect (Table [3](#CIW388TB3){ref-type="table"}). These data suggest that surveillance for emergence of *K13* mutations should be expanded to include *K13* regions outside the propeller domain. Third, 2 studies \[[@CIW388C15], [@CIW388C19]\] provide evidence that gametocyte carriage is elevated in parasites bearing *K13* mutations, leading to the suggestion that such parasites may have a transmission advantage. In contrast, in this large study from a single location, we observed no association between gametocyte carriage and *K13* mutations.

What are the implications of these data for the therapeutic life span of ACTs in Southeast Asia and beyond? The most widely deployed ACT is the coformulation of artemether and lumefantrine (AL), which has a resistance mechanism that is similar to that of mefloquine, involving *Pfmdr1* amplification \[[@CIW388C29], [@CIW388C33], [@CIW388C34]\]. In most areas where AL is used, there is no evidence for resistance to either component. However, in Myanmar where AL has recently been introduced, *K13* propeller mutants and *Pfmdr1* amplification are widespread \[[@CIW388C28], [@CIW388C35]--[@CIW388C38]\]. The therapeutic lifetime of AL in Myanmar and other areas with a high prevalence of *K13* mutations may be relatively short.

ACTs containing an alternative partner drug should provide relief in the short term. In 2012 the first-line treatment of uncomplicated *P. falciparum* malaria in our treatment centers on the Thailand--Myanmar border was changed from MAS3 to DHA--piperaquine, which is currently highly efficacious in this area but relies increasingly on the piperaquine component. The recent emergence of piperaquine resistance in Cambodia \[[@CIW388C39]\] and associated rising failure rates with DHA--piperaquine \[[@CIW388C19], [@CIW388C21], [@CIW388C40]\] also cast doubt over the long-term future of this combination. Alternatives are needed desperately. With new antimalarials still years from deployment, there is an urgent need to eliminate *P. falciparum* from the area before the recent and substantial gains in malaria control are reversed.

Supplementary Data {#s5}
==================

[Supplementary materials](http://cid.oxfordjournals.org/lookup/suppl/doi:10.1093/cid/ciw388/-/DC1) are available at <http://cid.oxfordjournals.org>. Consisting of data provided by the author to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the author, so questions or comments should be addressed to the author.
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[^1]: Abbreviation: CI, confidence interval.

[^2]: ^a^ Excluding patients not attending who were positive at the previous visit.

[^3]: The analysis of *K13* mutant subsets produced similar (within 10%) adjusted odds ratios for fever, year of recruitment, parasitemia, and hematocrit compared with those obtained for any *K13* mutant.

[^4]: ^a^ Compared with wild type.

[^5]: The analysis of *K13* mutant subsets and compound *K13/Pfmdr1* genotypes produced similar (within 10%) adjusted hazard ratios for age and year of recruitment compared with the main model.

[^6]: ^a^ Compared with wild type.

[^7]: ^b^ Compared with single *Pfmdr1* copy number and wild-type *K13*.
